ArticleFuture oncology (London, England)2025
Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dyadic Coping and Its Influencing Factors in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy and Their Spouses: A Latent Class Analysis.Journal of clinical nursing · 2026Observational
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives.Future oncology (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients with metastatic castration-resistant prostate cancer (mCRPC) and caregivers were surveyed to understand their attitudes, emotions, and experiences with the disease, its treatments, and their willingness to explore genetic testing.
methodsA non-interventional, cross-sectional, online, quantitative-qualitative survey was conducted from 17-February to 9March 2022 among patients (≥21-years old) with mCRPC (diagnosis for ≥3-months) and caregivers.
resultsA total of 221 patients with mCRPC and 159 caregivers from USA, France, Germany, Canada, Spain, China, and Brazil were surveyed. mCRPC impacts mood, emotional and mental health (50-77%), sleep (48-68%), career goals (48-80%), and social activities (46-65%). Primary symptoms/side effects are urination issues (trouble urinating: 33-60%; painful/burning urination: 32-50%, frequent urination: 27-50%) and sexual dysfunction (lower libido: 10-57%), which impact romantic relationships. Caregivers often spouses or partners, provide practical, financial, and emotional support, averaging 11 hours/week of providing care. Patients face high treatment and pill burden (7-12 pills/day) and prefer simpler treatment regimens. Hope motivates patients and genetic testing is one such avenue of hope.
conclusionmCRPC is a life-changing diagnosis with physical, psychological, and financial burdens. By encouraging early genetic testing and fostering patient-centered conversation, HCPs can provide personalized care for optimized treatment outcomes in mCRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.